| Quantitative analysis of lab-to-lab variability in Caco-2 permeability assays JB Lee, A Zgair, DA Taha, X Zang, L Kagan, TH Kim, MG Kim, H Yun, ... European Journal of Pharmaceutics and Biopharmaceutics 114, 38-42, 2017 | 82 | 2017 |
| Prevention of paclitaxel-induced neuropathy by formulation approach X Zang, JB Lee, K Deshpande, OB Garbuzenko, T Minko, L Kagan Journal of controlled release 303, 109-116, 2019 | 32 | 2019 |
| Physiologically-based modeling and interspecies prediction of paclitaxel pharmacokinetics X Zang, L Kagan Journal of pharmacokinetics and pharmacodynamics 45, 577-592, 2018 | 17 | 2018 |
| Next-generation islatravir implants projected to provide yearly HIV prophylaxis RP Matthews, X Zang, S Barrett, A Goodey, T Heimbach, V Weissler, ... Conference on Retroviruses and Opportunistic Infections (CROI), 6-10, 2021 | 14 | 2021 |
| Interspecies prediction of pharmacokinetics and tissue distribution of doxorubicin by physiologically‐based pharmacokinetic modeling JB Lee, S Zhou, M Chiang, X Zang, TH Kim, L Kagan Biopharmaceutics & Drug Disposition 41 (4-5), 192-205, 2020 | 13 | 2020 |
| A randomized, double-blind, placebo-controlled, phase 1 trial of radiopaque islatravir-eluting subdermal implants for pre-exposure prophylaxis against HIV-1 infection RP Matthews, X Zang, SE Barrett, A Koynov, A Goodey, T Heimbach, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 92 (4), 310-316, 2023 | 10 | 2023 |
| Islatravir PK threshold & dose selection for monthly oral HIV-1 PrEP M Patel, X Zang, Y Cao, RP Matthews, R Plank, P Sklar, J Grobler, ... Conference on Retroviruses and Opportunistic Infection, Virtual, 2021 | 10 | 2021 |
| Prediction of individual analgesic response to intravenous lidocaine in painful diabetic peripheral neuropathy: a randomized, placebo-controlled, crossover trial MS Todorovic, K Frey, RA Swarm, M Bottros, L Rao, D Tallchief, K Kraus, ... The Clinical journal of pain 38 (2), 65-76, 2022 | 7 | 2022 |
| Modeling and simulation to optimize islatravir once daily (QD) doses in HIV treatment naive and virologically suppressed populations R Vargo, S Robey, X Zang, L Du, J Roberts, S Klopfer, T Correll, ... JOURNAL OF THE INTERNATIONAL AIDS SOCIETY 25, 22-23, 2022 | 3 | 2022 |
| Physiologically-Based Modeling and Interspecies Prediction of Cisplatin Pharmacokinetics X Zang, L Kagan Journal of Pharmaceutical Sciences 113 (1), 158-166, 2024 | | 2024 |
| ISLATRAVIR INTRACELLULAR TRIPHOSPHATE T1/2 SUPPORTS EXTENDED DOSE INTERVALS. W Ankrom, X Zang, J Spiridigliozzi, W Kraft, R Vargo, A Stoch, M Iwamoto, ... CLINICAL PHARMACOLOGY & THERAPEUTICS 111, S59-S59, 2022 | | 2022 |
| Postprandial administration but not controlled release in the colon increases oral bioavailability of DF030263, a promising drug candidate for chronic lymphocytic leukemia J Bong Lee, X Zang, A Zgair, T Qian Ooi, DW Foley, G Voronin, L Kagan, ... European Journal of Pharmaceutics and Biopharmaceutics 165, 106-112, 2021 | | 2021 |
| Administration in fed state but not controlled release in the colon increases oral bioavailability of DF030263, a promising drug candidate for chronic lymphocytic leukemia JB Lee, X Zang, A Zgair, TQ Ooi, DW Foley, G Voronin, L Kagan, ... European Journal of Pharmaceutics and Biopharmaceutics 165, 106-112, 2021 | | 2021 |
| Quantitative Approaches for Understanding and Minimizing Chemotherapy-Induced Peripheral Neuropathy X Zang Rutgers The State University of New Jersey, School of Graduate Studies, 2019 | | 2019 |
| Physiologically-based modeling of cisplatin pharmacokinetics X Zang, L Kagan JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS 45, S118-S119, 2018 | | 2018 |
